April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL
July 8th 2021Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.
Watch
Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma
June 16th 2021Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.
Read More
Axi-Cel Outperforms Alternate Treatments in R/R Follicular Lymphoma
June 14th 2021Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Read More
CAR T Therapy Effective for Numerous Hematologic Malignancies, Even in Heavily Pretreat Patients
May 27th 2021In an interview with Targeted Oncology, Deepu Madduri, MD discussed the need for further CAR T-cell therapy research, expanding it into other hematology malignancies. She also discussd management of the common adverse events associated with CAR T cells.
Read More
FDA Grants Fast Track Designation to Novel CAR T-Cell Therapy for Thyroid Cancers
May 19th 2021The FDA has granted a fast track designation to the autologous chimeric antigen receptor T-cell agent, AIC100, for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
Read More
Safety/Feasibility of CAR T-Cell Therapy Being Investigated in Brain Tumors
May 18th 2021The first patient has been dosed in a study designed to evaluate the safety and feasibility of IL13Rα2 chimeric antigen receptor T cell therapy for the treatment of leptomeningeal brain tumors, such as glioblastoma, ependymoma, and medulloblastoma.
Read More
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World Settings
May 15th 2021Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Read More
Liso-Cel Efficacy Not Impacted by Prior CD19 Exposure in LBCL
April 25th 2021In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.
Read More
When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
Immune System Plays Important Role in CAR T Cell Responses in Glioblastoma Models
April 16th 2021Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.
Read More
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL
April 12th 2021Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
Watch
Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel
March 24th 2021In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.
Read More
Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCL
March 24th 2021Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.
Read More
Exploring the Potential of PSCA-Targeted CAR T-Cell Therapy to Treat mCRPC
March 23rd 2021Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.
Read More
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond
March 6th 2021The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Read More